What changed this week, straight from the source.

A meta-analysis of 23 randomized controlled trials involving 1,723 participants found that liraglutide significantly reduced systolic blood pressure and improved various renal and metabolic biomarkers in patients with type 2 diabetic nephropathy.

McGill University Health Centre registered a 24-week clinical trial enrolling 40 adults to evaluate how semaglutide affects body composition in people with type 1 diabetes and overweight or obesity compared to a placebo.

Assisting Nature registered a trial for 180 participants to test a physiology-oriented mild ovarian stimulation protocol. The trial investigates whether a late-start protocol with corifollitropin alfa can simplify IVF while maintaining clinical outcomes.

Researchers published a pilot study finding that cutaneous follistatin expression was reduced by approximately 225.59-fold in the lesional skin of patients with striae gravidarum compared to control skin, suggesting a role in the condition's pathogenesis.

The Expert Council of the National Association of Pediatric Neurologists stratified Cerebrolysin into Group B, representing medications for ADHD with a limited evidence base, to be used only within a multidisciplinary approach.

A study found that MOTS-c protects against diabetic kidney injury in mice by downregulating LARS1, which promotes lipophagy and reduces tubular senescence and lipid deposition.

A study in The Journal of biological chemistry explored how humanin variants regulate BID fibrilization and membrane permeability. Findings showed that humanin reduces BAX- and tBID-mediated membrane permeabilization, integrating residue-level determinants into a framework for apoptosis regulation.

LMC Diabetes & Endocrinology Ltd. registered an observational study to evaluate the effectiveness of switching from injectable semaglutide to tirzepatide in 650 adults living with type 2 diabetes and obesity.

Hoffmann-La Roche registered a phase 3 randomized clinical trial to evaluate the safety and efficacy of enicepatide compared to tirzepatide in 948 participants with type 2 diabetes who have inadequate glycemic control on oral medications.

A randomized clinical trial involving 72 participants found that semaglutide treatment in patients with major depressive disorder resulted in increased exploitation and directed exploration behaviors. The study highlights the role of metabolic mechanisms in decision-making processes for MDD.

New randomized trial in Women's health (London, England): Oxytocin selectively enhances the recognition of infant sadness in postpartum depression.

Phase 3 trials TRIUMPH-1-OSA and TRIUMPH-2-OSA found that once-weekly retatrutide significantly reduced the apnea-hypopnea index in adults with moderate-to-severe obstructive sleep apnea compared to placebo.

An editorial in the journal Hypertension discusses how follistatin-mediated browning of adipose tissue can contribute to improved cardiometabolic health.

A compounder issued a recall for a copycat version of Zepbound following concerns about the safety of such knockoff weight loss drugs.

Fudan University registered a phase II clinical trial to evaluate the safety and efficacy of thymalfasin combined with chemotherapy and immunotherapy in 572 patients with triple-negative breast cancer. The study will compare 3-year event-free survival between treatment groups.

A systematic review and meta-analysis of three randomized controlled trials found that mazdutide led to greater reductions in HbA1c and body weight compared to dulaglutide in adults with type 2 diabetes. Mazdutide was associated with higher rates of gastrointestinal side effects.

Diabetes, obesity & metabolism published an erratum correcting a previous secondary, post hoc analysis of the REDEFINE 1 trial regarding the efficacy of CagriSema.

Researchers published a study showing that the peptide elamipretide reduced cisplatin-induced ovarian failure in a mouse model. The treatment preserved mitochondrial function and increased the number of follicles by activating the Nrf2/HO-1 signaling pathway.

A multicenter phase 4 study found that weekly 0.5 or 1 mg subcutaneous semaglutide injections significantly improved HbA1c, fasting blood glucose, and weight in 104 Chilean patients with type 2 diabetes.

A randomized trial evaluating the GnRH agonist leuprorelin in women with polycystic liver disease was terminated early after finding the treatment did not reduce liver volume and was associated with severe menopausal side effects and adverse events.

Massachusetts General Hospital registered a pilot study enrolling 40 adults to determine if semaglutide affects brain reactivity to cannabis-related cues and reduces the frequency of cannabis use in individuals with cannabis use disorder.

Dsm-firmenich Switzerland AG registered a Phase 1 study to evaluate the effects of trigonelline monohydrate on NAD+ metabolism, safety, and pharmacokinetics in 60 healthy adults aged 40 to 70. Participants will receive one of four doses of the supplement, an NMN comparator, or a placebo for 4 weeks.

Eli Lilly and Company registered a Phase 3 trial to investigate the safety and efficacy of eloralintide and tirzepatide coformulation compared with tirzepatide, eloralintide, and placebo in 2115 adults with obesity.

Eli Lilly and Company registered a Phase 3 study to evaluate the efficacy and safety of eloralintide and tirzepatide coformulation compared to tirzepatide in 1000 adults with obesity or overweight and type 2 diabetes.

Novo Nordisk A/S registered an observational study of 10000 adults in Australia to generate real-world evidence on the use of semaglutide among people receiving care through a digital weight loss service.

Laboratory experiments using aged mouse eggs and human granulosa cells showed that MOTS-c boosted energy production and supported egg maturation, though further research is needed for human fertility applications.

Researchers published a letter in Diabetes, obesity & metabolism regarding the interpretation of survodutide renoprotection in a hyperfiltration model.

Researchers studied male and female lambs and found that undernutrition increased AgRP neuron input to arcuate kisspeptin neurons. This mechanism likely relays negative energy status to the reproductive axis to inhibit GnRH/LH secretion.

New randomized trial in Medicine: Hyaluronic acid-based skin booster with glutathione combined with 1064-nm Nd:YAG laser and oral tranexamic acid for melasma: A prospective comparative study.

Clinicians reported a case of a 65-year-old woman whose nonfunctional pancreatic neuroendocrine tumor transformed into a vasoactive intestinal peptide-secreting tumor. Following a living donor liver transplantation, her symptoms resolved and did not recur for 1 year.

New meta-analysis in Frontiers in endocrinology: CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.

Researchers published a case report of a 57-year-old man who experienced rapid neurological improvement after receiving adjunctive Cerebrolysin following mechanical thrombectomy for a stroke. The therapy was used to address persistent tissue-level hypoperfusion.

A narrative review of Epitalon and Epithalamin found that while Epitalon is biologically active in modulating aging markers in preclinical studies, it remains clinically unproven in humans. No adequately powered randomized trial has established therapeutic efficacy.

New systematic review in Acta orthopaedica Belgica: Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety.

Researchers assessed the effects of adjunctive physiotherapy after glaucoma surgery in 50 patients. The physiotherapy course, which included the peptide Semax, improved mean deviation in retinal function for up to 6 months post-surgery.

Researchers evaluated the stability of liposome-encapsulated GHK-Cu in cosmetic formulations using capillary electrophoresis coupled with mass spectrometry. The study demonstrates that liposomes can successfully encapsulate GHK-Cu, potentially enhancing transdermal delivery.

University Hospital, Clermont-Ferrand terminated a Phase 4 randomized controlled trial comparing balloon catheter plus oxytocin to oral misoprostol for labor induction in nulliparous women due to futility.

Sponsor Praful Ravi terminated a phase 1/2 study of darolutamide and abemaciclib in 9 prostate cancer patients after drug provider Lilly withdrew funding and support for the trial.

The study of darolutamide and abemaciclib for prostate cancer was terminated because the funding company, Lilly, withdrew support based on new data regarding abemaciclib in advanced prostate cancer.

M.D. Anderson Cancer Center registered a phase 2 feasibility trial to study the use of tirzepatide for preventing overweight and obesity-associated cardiotoxicity in 30 adolescent and young adult cancer survivors. The study focuses on those who have completed chemotherapy.

Morten Hostrup registered a trial to study the long-term effects of semaglutide on body composition, running performance, and hormonal markers in 41 well-trained athletes. This research aims to address the unknown impact of semaglutide on physical performance in lean, fit runners.

Morten Hostrup registered a trial to investigate the short-term effects of semaglutide on body composition and exercise performance in 41 well-trained male and female runners. The study aims to determine how the drug influences muscle mass and function during caloric restriction.

Researchers developed an ELISA method to detect the peptide CJC-1295 in equine plasma at concentrations as low as 12.5 pg/mL. The assay was validated using blood samples from thoroughbred racehorses administered 10 mg of the peptide.

New systematic review in Basic & clinical pharmacology & toxicology: Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis.

A review and case report published in Frontiers in oral health examined the use of regenerative peptides like BPC-157, TB-500, and ARA-290 for inferior alveolar nerve injury. The authors reported neurosensory recovery in three clinical cases but cautioned that causality cannot be established.

A systematic review published in Frontiers in Neurology details the role of NAD+ depletion in Parkinson's disease pathogenesis. It summarizes evidence that NAD+ precursors like nicotinamide riboside and NMN may offer neuroprotective effects in disease models.

A study in streptozotocin-induced diabetic rats found that retatrutide significantly lowered HIF-1α expression in kidney tissue but did not provide statistically confirmed histopathological protection against renal injury.

Sponsor Signe Torekov registered a phase 4 randomized controlled trial to investigate an enhanced family care intervention combined with semaglutide or placebo for intergenerational obesity, aiming to enroll 400 participants.

Ankara City Hospital Bilkent is planning an observational study of 120 pregnant women to compare how dural puncture epidural analgesia affects maternal plasma oxytocin levels during early versus late stages of labor.

Centric Compounding LLC initiated a voluntary recall of Tri-Immune Boost, containing glutathione, ascorbic acid, and zinc, due to microbial contamination. Out of specifications results for bacterial endotoxin were obtained during testing.

Carolina Infusion, LLC initiated a class II recall of various semaglutide and semaglutide/cyanocobalamin injectables. The firm cited a lack of assurance of sterility related to the use of bacteriostatic water and processing equipment.

Apothecary Pharma LLC initiated a nationwide Class II recall of Apothecary NAD+ Injection 200 mg/mL, 6 mL sterile multi-dose vials. The recall was issued due to a lack of assurance of sterility.

Researchers treated H9c2 cardiomyocytes with 50 or 100 nM Kisspeptin-10 and found it alleviated injury induced by oxygen-glucose deprivation/reperfusion. The study indicates this occurred by enhancing autophagy through the YY1/TFEB axis.

A review published in the Journal of Diabetes and Metabolic Disorders analyzed the progress and challenges in developing pediatric anti-obesity medications. It emphasized the need to verify the safety and efficacy of GLP-1 agonists and multi-target drugs like mazdutide through pediatric trials.

A cross-sectional study in JAMA Network Open evaluates self-reported adverse effects among social media users who utilized nonapproved retatrutide.

A study published in Diabetes, Obesity & Metabolism found that the dual GLP-1R/GCGR agonist mazdutide decreased circulating cholesterol levels and attenuated liver steatosis in mice with metabolic dysfunction-associated steatotic liver disease.

Wake Forest University Health Sciences terminated a 4-participant study on the pharmacodynamics of oxytocin for chronic knee pain. The study was stopped due to funding and competing NIH grant work.

Universitaire Ziekenhuizen KU Leuven registered a Phase 4 study to determine how semaglutide affects eating behavior and weight regulation in 96 participants with obesity or overweight. Researchers are investigating which patients respond best to semaglutide treatment over 6 months.

Sheba Medical Center completed a Phase 2 trial of an algorithmic polytherapy regimen involving semaglutide and other agents in 31 healthy aging participants. The study characterized individual responses to these interventions over approximately 8 weeks.

New systematic review in BMJ medicine: Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review.

Researchers developed HyM 2 Surv, a hypergraph-based framework for survival prediction that integrates pathological images and microbiome data. This model outperformed state-of-the-art methods by an average of 6.10% in C-index across four TCGA datasets.

Researchers reviewed evidence linking the LL-37 peptide and MRGPRX2 receptor signaling to mast cell activity in rosacea. The study noted that while animal models support this pathway, direct selective functional testing in human rosacea patients is currently lacking.

A narrative review of 76 studies on peptide use in urology and sexual medicine found that while some agents like Bremelanotide and Tesamorelin have clinical backing, many others like CJC-1295 remain unvalidated and accessible only through unregulated markets.

Researchers found that knocking down Slc32a1 in female mice caused earlier vaginal opening and upregulated puberty-related genes including Kiss-1. The findings suggest SLC32A1 regulates puberty onset by modulating GnRH neuron function via GABA-GABA B receptor signaling.

Researchers published a study in Neuroscience showing that humanin mitigates cellular senescence in neuronal cells. Chronic treatment with the humanin derivative HNG sustained neurotransmitter release and synapsin expression in differentiated PC12 cells exposed to glutamate.

A letter published in Diabetes, obesity & metabolism explores whether survodutide provides renoprotection beyond its known metabolic and haemodynamic effects in patients with diabetic kidney disease.

A narrative review published in Obesity Reviews examines the role of dual glucagon and GLP-1 receptor agonists in treating obesity and metabolic dysfunction-associated steatohepatitis. The review highlights that mazdutide and survodutide show potent weight-loss and antihyperglycemic effects.

Researchers identified cathelicidin (CAMP) as an age-dependent regulator of bone repair in mice. CAMP promotes fracture healing in young animals by supporting osteogenesis, but it constrains healing in aged animals.

Istanbul University-Cerrahpasa registered a trial of 136 participants to evaluate the effects of various massage techniques on breastfeeding and mother-infant bonding. The study compares maternal and infant massage, oxytocin massage, or both against standard care.

Novo Nordisk A/S registered a phase 1 study to assess the tolerability of switching 60 participants with overweight, obesity, or type 2 diabetes from their current maintenance dose of tirzepatide to a new treatment called zenagamtide.

A JAMA article outlines the risks and reasons behind the growing black market for unapproved GLP-1 weight loss drugs, including retatrutide and zenagamtide.

Researchers published a study on the tripeptide Lysine-Proline-Valine in macrophage models. Treatment with the peptide attenuated lipid accumulation and foam cell formation by suppressing reactive oxygen species and inflammatory signaling pathways.

Amgen registered a Phase 3 trial to compare the efficacy and safety of once-monthly maridebart cafraglutide against once-weekly semaglutide in 1300 participants with type 2 diabetes. The study aims to evaluate if the monthly treatment is non-inferior to semaglutide for glycemic control.

Shanghai Zhongshan Hospital registered a randomized, controlled trial to test if adding 1.6 mg of thymalfasin twice daily for 7 days improves immune recovery in 60 adults with sepsis and immune function impairment.

The National Medical Research Center for Therapy and Preventive Medicine began a study comparing the effectiveness of tirzepatide and transcutaneous auricular vagus nerve stimulation in 120 adults with class I obesity.

A cross-sectional study of 55 women with PCOS and 50 with idiopathic hirsutism compared to 50 controls found that AMH levels were higher in PCOS patients than in the hirsutism group. Inhibin A and inhibin B levels were significantly higher in both patient groups compared to controls.

Researchers mapping radiation-induced brain injury in mice discovered that the blood-cerebrospinal fluid barrier is compromised during the early-delayed phase following irradiation. This disruption is caused by the depletion of a radiosensitive Tmsb4x-positive epithelial cell population.

Researchers published an article in The Lancet discussing findings from the TRIUMPH-2 clinical trial regarding retatrutide in adults with obesity and type 2 diabetes.

Researchers found that chicken cathelicidin-3 (cCATH-3) protected 80% of mice from APEC infection compared to 20% survival for cCATH-1. This protection occurred through CCL3-mediated macrophage chemotaxis and enhanced bacteriocidal activity.

A BMJ case report details a woman who experienced persistent nausea and vomiting after self-administering unverified retatrutide injections obtained from a non-medical practitioner. The Naranjo score of 7 indicated probable causality.

Al-Azhar University registered a randomized controlled trial of 100 participants to compare the reproductive outcomes of a dual trigger versus a conventional hCG trigger for oocyte maturation in normal responders.

Researchers analyzing K14-Cre-mediated follistatin (Fst) knockout mice found that Fst regulates tooth root furcation by modulating Shh and Wnt signaling. Mutant mice exhibited molar root abnormalities, including enlarged pulp chambers and partial furcation defects.

Researchers published the design and baseline characteristics of the REDEFINE 3 trial, a study investigating the cardiovascular safety and efficacy of CagriSema. The trial randomized 7076 adults with cardiovascular disease between 1/2023 and 12/2024.

Researchers studied mice fed a high-fat diet and found time-dependent, discordant regulation of the activin-follistatin axis and GDF15 in fatty liver disease. The findings highlight a mismatch between hepatic mRNA levels and circulating protein levels over 30 weeks.

Kristin Clemens registered a trial to test a weight loss program combining semaglutide and virtual coaching for 880 patients with obesity and advanced kidney disease. The study aims to help patients achieve a healthier body weight to facilitate potential kidney transplantation.

Istanbul Saglik Bilimleri University registered a prospective descriptive study of 42 participants to assess the relationship between GLP-1 receptor agonist use and sarcopenia in non-diabetic individuals with obesity. Researchers will evaluate body composition changes over 3 months.

The General Committee of Teaching Hospitals and Institutes in Egypt registered a Phase 4 randomized, placebo-controlled trial (NCT07859137) enrolling 100 patients with a BMI of 60 kg/m² or higher. The study will evaluate the safety and feasibility of using semaglutide before bariatric surgery.

The General Committee of Teaching Hospitals and Institutes in Egypt registered a Phase 4 trial (NCT07859150) enrolling 104 participants to study semaglutide 2.4 mg for recurrent weight gain after bariatric surgery. It is a randomized, double-blind, placebo-controlled study.

The General Committee of Teaching Hospitals and Institutes in Egypt registered a trial to evaluate semaglutide for recurrent weight gain in 100 patients after sleeve gastrectomy surgery. The study compares the drug to a placebo before and after conversion to Roux-en-Y gastric bypass.

The General Committee of Teaching Hospitals and Institutes in Egypt registered a Phase 4 randomized trial with 100 participants to compare tapered versus abrupt discontinuation of semaglutide. The study investigates strategies for stopping treatment after weight regain following bariatric surgery.

The General Committee of Teaching Hospitals and Institutes in Egypt registered a Phase 4 trial (NCT07859189) enrolling 100 participants. It compares immediate semaglutide treatment versus criterion-triggered treatment for patients with suboptimal weight loss 1 year after bariatric surgery.

Researchers studied AVPV kisspeptin neurons in mice and found that GnRH neuron responsiveness to kisspeptin activation relies on both the hormone environment and synaptic connectivity. The study also determined that neuromodulatory transmission can occur without fast-synaptic co-transmission.

Researchers published a study demonstrating that elamipretide improves oocyte quality and fertility in aged mice, human, and porcine models. The peptide restores ovarian function by activating the VEGF signaling pathway to enhance mitochondrial metabolism and organelle organization.

Assiut University registered a 100-participant study to examine the effect of intravenous oxytocin on post-dural puncture headache following cesarean sections. The study is not yet recruiting.

Novo Nordisk A/S registered a phase 1 clinical trial enrolling 60 participants to determine which dose of zenagamtide can be substituted for a maintenance dose of semaglutide in adults with overweight or obesity.

Boehringer Ingelheim registered a phase 3 trial to evaluate initiation strategies for survodutide, including new use or switching from semaglutide or tirzepatide, in 350 adults with obesity but no diabetes. The study aims to determine if survodutide helps these participants lose weight.

Researchers published a case report of an 80-year-old female with a pheochromocytoma-ganglioneuroma tumor that secreted vasoactive intestinal peptide. Surgical removal of the mass resolved her chronic diarrhea, hyponatremia, and hypertension.

Researchers found that adding an N-terminal biphenyl motif from LL-37 to a short cathelicidin derivative improves activity against gram-negative bacteria by >16-fold. The biphenyl pharmacophore increases membrane permeabilization in the 14-mer peptide without affecting its stability.

A phase 3 trial published in The New England journal of medicine showed that weekly survodutide doses of 3.6 mg or 6.0 mg resulted in significant weight reduction in adults with obesity and type 2 diabetes. Mean weight change at week 76 was -8.2% and -9.8% respectively, versus -3.9% for placebo.

A study in Contemporary clinical trials reviewed the mechanistic rationale and clinical evidence for survodutide. In a phase 2 trial, participants without diabetes receiving a 4.8-mg dose achieved a mean body-weight reduction of 18.7% at 46 weeks, compared to 2.3% for placebo.

New paper in Diabetes, obesity & metabolism: Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.

Researchers used a genetic approach to show that Streptococcus pyogenes protease SpeB does not significantly impact the killing of the bacteria by the peptide LL-37. Even though SpeB cleaves LL-37, the bacterial CovRS system maintains its sensitivity to the resulting LL-37 fragments.

The National Hospital of Acupuncture in Vietnam registered a randomized controlled trial for 440 patients to evaluate the efficacy of combined electroacupuncture, acupressure, and acupoint injections of Cerebrolysin or B-complex vitamins for post-acute ischemic stroke rehabilitation.

Researchers found that a subset of SCN neurons releases GABA to potently suppress firing in RP3V kisspeptin neurons in female mice. These findings reveal that this specific circadian neuronal population provides a direct inhibitory input to the kisspeptin network.

A review published in Diabetes Therapy examines the efficacy of amylin-based agonists, reporting that eloralintide achieved weight loss of up to 20.1% in a phase 2 study. The authors note the drug is associated with fatigue, headache, and appetite loss.

A critical review of rodent studies associated BPC-157 with protective effects against ischemia-reperfusion injury, including reductions in inflammation and oxidative stress. The authors noted the evidence remains heterogeneous and preclinical.

Researchers studied the effects of Humanin in mice with Klebsiella pneumoniae infection and in 20 human patients. They found that Humanin pretreatment reduced liver injury, decreased NF-κB inflammatory signaling, and prolonged survival in the mice.

A systematic review of GHK-Cu literature through August 12, 2026, found that while preclinical data supports its role in tissue repair, clinical evidence remains limited. The review highlights that many delivery studies fail to resolve critical factors like molar copper occupancy.

A scoping review of 26 clinical publications characterized the use of Thymosin Alpha 1 as an adjunctive cancer therapy, finding it is most commonly administered via subcutaneous injection and used alongside various anticancer treatments, though standardized prospective studies are needed.

Researchers studied mice with hepatic Echinococcus granulosus infection and found that the GHSR antagonist [D-Lys3]-GHRP-6 effectively slowed disease progression by inhibiting liver cell proliferation and promoting beneficial fibrosis.

Changchun GeneScience Pharmaceutical Co., Ltd. registered a Phase 3 clinical trial to evaluate the efficacy and safety of once-weekly PEG-hGH injection compared to once-daily hGH injection in 105 children with short stature due to small for gestational age.

A systematic review of GHK-Cu literature published between 2005 and 2026 identified a lack of adequately powered human trials using microneedle delivery. Researchers found extensive preclinical evidence for tissue regeneration but noted that further clinical testing is required.

Beijing Children's Hospital registered a Phase 2 trial of 180 children to determine if injectable nicotinamide adenine dinucleotide is safe and effective for treating cardiac dysfunction. The multicenter study will assess the supplement alongside standard heart failure care.

Researchers identified that craniofacial involvement in extranodal diffuse large B-cell lymphoma is an independent adverse prognostic factor for survival. Patients with this involvement showed more frequent mutations in MYD88, TMSB4X, and PCLO.

Researchers assessed the clinical significance of vasoactive intestinal peptide and 5-hydroxytryptamine in 30 patients with diabetic neurogenic bladder. Combined detection provided better diagnostic efficacy (AUC 0.878) than single-marker tests and correlated with disease severity.

A study published in the Chinese Medical Journal found that MOTS-c mediates protection against lung ischemia-reperfusion injury through NRF2-dependent mitochondrial biogenesis.

New paper in Diabetes, metabolic syndrome and obesity : targets and therapy: Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials.

Researchers developed and evaluated MC1R-targeted radiopharmaceuticals using 203Pb and 212Pb for potential melanoma therapy. The study identified compound 9, a derivative of NDP-MSH, as having high binding affinity and low accumulation in healthy organs in mouse models.

New review in Missouri medicine: Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.

Researchers published a study in the Journal of molecular histology evaluating Hexarelin in mice with MPTP-associated pancreatic injury. Findings showed that Hexarelin treatment attenuated pancreatic inflammation and apoptosis while partially preserving islet morphology.

A meta-analysis of 30 studies comprising 3,287 patients found that once-weekly long-acting growth hormone has comparable efficacy and safety to daily growth hormone in children with short stature. The study noted that long-acting versions may improve treatment convenience and adherence.

A case report describes a 69-year-old man with post-traumatic aphasia who showed significant language improvement after a 21-day course of intravenous Cerebrolysin alongside speech therapy. His Aphasia Quotient rose from 66.2 to 97.1 by day 28.

A study in HTR-8/SVneo cells found that ghrelin treatment at 1000 nmol/L protects trophoblasts against hypoxia-induced mitochondrial damage, oxidative stress, and apoptosis by downregulating TGFB2.

Researchers published a study showing that daily co-administration of cagrilintide and retatrutide in diet-induced obese male rats produced greater weight loss and improved metabolic markers compared to monotherapies or combinations with semaglutide or tirzepatide.

A review in Cardiology in Review evaluates early studies of eloralintide, noting potential cardiometabolic benefits including reductions in body weight, blood pressure, and pulse rate. The authors emphasize that no dedicated cardiovascular outcomes trial has been conducted.

Eli Lilly and Company completed a phase 2 study investigating the safety and efficacy of LY3841136 and tirzepatide, alone or in combination, for weight management in 367 adults with obesity or overweight and type 2 diabetes.

Novo Nordisk A/S registered a phase 3 study with 210 participants to examine the safety and tolerability of switching from semaglutide to CagriSema in people with type 2 diabetes.

A study of 154 patients hospitalized for chronic heart failure found that a standardized rehabilitation protocol involving exercise and nutritional support improved physical performance compared to a control group and helped evaluate the prognostic value of the Humanin/CRP ratio.

A study of 69 patients found that when the insulin tolerance test is contraindicated, clinicians can use the GHRP-2 stimulation test to help diagnose hypothalamic secondary adrenal insufficiency, where a peak cortisol level below 12 μg/dL is specific to this condition.

Zhongshan Sansure Hygene Biomedicine Co., Ltd. registered a Phase 3 clinical trial to evaluate the efficacy and safety of daily human growth hormone injection, Sinotropin AQ, in 240 pediatric participants with idiopathic short stature.

Optimal Balance Pharmacy initiated a Class I recall of 53 vials of glutathione 200 mg/mL injection due to microbial contamination. The pharmacy found out of specifications results for bacterial endotoxin.

Researchers developed biodegradable polymer STAR particles-using materials like cellulose acetate and polylactic acid-to painlessly puncture skin and deliver drugs. Tests showed these particles increased intradermal drug delivery of agents like copper tripeptide-1 by up to 37-fold.

A systematic review of 10 studies found that growth hormone deficiency is linked to specific patterns of craniofacial underdevelopment and delayed dentofacial maturation. Researchers concluded that growth hormone therapy may partially normalize several of these craniofacial parameters.

Scientific Reports published a correction regarding a study linking reduced MOTS-c levels in women with polycystic ovary syndrome to mitochondrial dysfunction.

A study in aged mice with metabolic dysfunction-associated steatotic liver disease found that both MitoQ and SS-31 improved liver health, with MitoQ enhancing antioxidant defenses and SS-31 preserving mitochondrial structural integrity.

Researchers identified a novel, highly conserved linear B-cell epitope on the rabies virus glycoprotein using monoclonal antibodies. This finding provides a potential molecular target for the design of next-generation epitope-based vaccines and diagnostic tools.

A randomized controlled trial showed that Phellinus igniarius decoction effectively restored immune function and improved quality of life in colorectal cancer patients following chemotherapy, with patients suffering from spleen-kidney deficiency syndrome responding best.

Researchers identified that Thymosin Alpha 1 acts as a non-canonical ligand for the Hypocretin Receptor 1, protecting neurons from cell death in ischemic stroke models by suppressing the activity of Receptor-Interacting Protein Kinase 3.

A review of pharmacological treatments for diabetic neuropathy analyzed roughly 107 articles on approved and experimental therapies. The study highlighted that while agents like Cibinetide show potential for nerve repair, current treatments mostly focus on symptom management.

A review article published in Alpha psychiatry discusses the antidepressant mechanism of low-dose ketamine. The authors hypothesize that ketamine acts on astrocyte mitochondria to upregulate humanin, adenosine, and melatonin, which restores cellular function and reduces inflammation.

The University of Arkansas registered a phase 1 trial to investigate the safety, feasibility, and preliminary efficacy of BPC-157 in 30 participants undergoing arthroscopic rotator cuff repair surgery.

A narrative review of pharmacological treatments for severe traumatic brain injury examined human evidence for several agents, including Cerebrolysin, and proposed a modular framework for future development. The authors caution against routine off-label polypharmacy.

Researchers studied the effects of a 16 mg subcutaneous afamelanotide implant on UVR-induced skin responses in 9 healthy humans. The study found that afamelanotide significantly decreased the UVR-erythema dose response and increased melanin density six days after administration.

The University of Calgary registered an observational study involving 200 participants to characterize the impact of growth hormone deficiency on quality of life and sleep in adults with traumatic brain injury.

ReGenTree, LLC completed a phase 3 clinical trial involving 700 participants to assess the safety and efficacy of RGN-259 ophthalmic solutions for dry eye syndrome. Results were posted on August 28, 2026.

A narrative review summarized the current evidence on regenerative peptides used for chronic pain management. The authors concluded that clinical evidence in humans remains limited and most of these therapies currently lack FDA approval.

This review article discusses the potential of MOTS-c as a therapeutic candidate for sepsis-induced cardiomyopathy, noting that its translational relevance requires further disease-specific validation.

The Food and Drug Administration announced the renewal of the Cardiovascular and Renal Drugs Advisory Committee. This committee is extended for an additional 2 years, with the new charter remaining in effect until August 27, 2028.

Researchers developed an intranasal vaccine platform using a vasoactive intestinal peptide-nucleocapsid fusion protein to deliver circRNA. In mice, this vaccine induced systemic and mucosal immunity against RSV and significantly reduced pulmonary viral burden and lung inflammation.

A study in the Journal of basic and clinical physiology and pharmacology examined Hexarelin against MPTP-induced lung injury in mice. Hexarelin reduced histopathological damage and improved immunohistochemical parameters by mitigating oxidative stress, inflammation, and apoptosis.

Scientists found that the peptide NDP-MSH reduced depressive-like behaviors and neuroinflammation in a mouse model of depression. This therapeutic effect relies on activating the MC1R-cAMP/PKA signaling pathway in the prefrontal cortex.

Novo Nordisk A/S completed a phase 1 trial (NCT07605052) that evaluated the blood levels of two different presentations of cagrilintide in 50 participants living with overweight or obesity.

Victory Medical Center Pharmacy initiated a Class I recall of 91 vials of glutathione 200 mg/mL solution because of microbial contamination. The firm identified the issue after obtaining out of specifications results for bacterial endotoxin.

Researchers demonstrated that recombinant human thymosin beta-4 improves survival and reduces intestinal fibrosis in mice with colitis by suppressing mineralocorticoid receptor signaling. The study notes that TMSB4X is typically downregulated in colonic tissues of IBD patients.

Authors reported two pediatric cases of neuroblastoma where the patients presented with chronic secretory diarrhea. The report highlights that VIP-secreting neuroblastic tumors should be considered in the differential diagnosis of children with unexplained, treatment-resistant diarrhea.

Researchers conducted a randomized, blinded, placebo-controlled trial finding that Liraglutide did not improve stimulated C-peptide levels in 18 adults with long-standing type 1 diabetes after 52 weeks. Exploratory analyses suggested a steeper decline in C-peptide with Liraglutide than placebo.

New paper in Annals of medicine and surgery (2012): Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Researchers published a study on the peptide KPV in preadipocytes and obese mice. Treatment with 100 μg/mL KPV suppressed adipocyte differentiation and reduced triglyceride content by approximately 38% in vitro, while oral administration alleviated diet-induced obesity in mice.

A scoping review concluded that claims regarding peptide supplements for musculoskeletal recovery remain unsubstantiated by current human trials. Authors warned of potential risks including cardiovascular complications.

Lumos Pharma registered a phase 2 trial to evaluate the efficacy and safety of LUM-201 as an adjunct to oral semaglutide in 202 obese adults between the ages of 60 and 85 years. The study is not yet recruiting.

Reviewers examined 151 randomized controlled trials for vitiligo published between 2013 and 2023. They found that several interventions, including implanted afamelanotide, improved clinical scores when added to phototherapy, but no systemic monotherapies were superior to their comparators.

New systematic review in Journal of endocrinological investigation: Analysis of the efficacy and safety of liraglutide, semaglutide, and tirzepatide for the treatment of overweight and obesity: a systematic review and network meta-analysis.

Novo Nordisk A/S completed a phase 2 trial (NCT06797869) with 142 participants to investigate the effects of CagriSema compared to a placebo in individuals with type 2 diabetes and painful diabetic peripheral neuropathy.

In a rat study, researchers evaluated the effects of BPC-157 and TB-500 on Achilles tendon healing. Both treatments were associated with improved histopathological parameters and extracellular matrix organization, though the combination of peptides did not provide additional benefits.

A meta-analysis of four clinical trials involving 909 people with HIV found that tesamorelin reduced harmful abdominal visceral fat, waist circumference, and trunk fat while increasing lean body mass. The study noted the drug also led to modest improvements in cholesterol levels.

The FDA announced the availability of additional revised draft product-specific guidances. These documents provide recommendations for industry on designing bioequivalence studies to support abbreviated new drug applications.

A narrative review in Antioxidants evaluates FOXO4's role in redox-sensitive signaling and senescent-cell survival. It concludes that while FOXO4-DRI shows preclinical senolytic activity, clinical validation is required due to limited evidence on its antioxidant target genes.

Clinuvel Europe Limited completed a phase 1/2 trial to evaluate the pharmacokinetics of a 16mg afamelanotide implant in 28 adolescent and adult patients with erythropoietic protoporphyria. Results for the study, which ended January 20, 2025, were posted on July 27, 2026.

Researchers developed a stability-indicating RP-HPLC method to characterize bremelanotide degradation. Forced degradation studies revealed 8 degradation products, with major pathways involving deacetylation, peptide-bond hydrolysis, oxidation, and epimerization.

A case report describes a 62-year-old bodybuilder who developed dysphagia from anterior cervical osteophytes, raising the hypothesis that his 20-year history of exogenous growth hormone and GH secretagogue use may have contributed to significant bone growth.

A study found that treatment with 1 µM of SS-31 attenuated senescence markers, mitochondrial ROS production, and mitochondrial respiration elevation in cardiomyocytes treated with 50 nM doxorubicin.

Reus Research registered a study involving 80 healthy adults to assess the absorption, safety, and efficacy of an oral NAD+ supplement. The trial will compare NAD+ levels in whole blood against a placebo over 56 days.

Researchers published the protocol for the TRIUMPH trial, which will examine the effect of tesamorelin combined with exercise in 100 sedentary older adults living with HIV. The study measures physical function, muscle quality, and biological endpoints at 24 and 48 weeks.

A review of peptides modulating the GH-IGF-1 axis highlights the significant gap between clinical evidence and unregulated self-administration protocols. Clinicians are advised to recognize potential adverse effects like endocrine disturbances, fluid retention, and metabolic issues.

Researchers found that moderate doses of the ghrelin receptor agonist ibutamoren increased cost sensitivity in rats during conflict-based decision-making. This effect was linked to increased neuronal activity in dorsomedial striosomes.

New paper in Molecular carcinogenesis: Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence.

The Affiliated Nanjing Drum Tower Hospital completed a randomized controlled trial of 396 participants evaluating the effects of Liraglutide, Empagliflozin, and Linagliptin on cognitive function in patients with Type 2 Diabetes and mild cognitive impairment.

Researchers published a pilot trial of 22 subjects comparing 10 weeks of 1 mg tesamorelin against placebo for cognition. While low-dose treatment was not directly linked with significant changes in measures, machine learning analysis identified potential brain changes.

A study of 42 patients undergoing surgery for retinal detachment found that a combined physiotherapy approach, involving heliox therapy and the peptide Semax, improved visual acuity and microperimetry results compared to using Semax drops alone.

Scientists synthesized 14 macrocyclic peptide analogs based on MT-II, SHU-9119, and PG-901 scaffolds to target human melanocortin receptors. The novel compounds FM648 and FM636 emerged as potent, selective hMC4R antagonists, while FM635 demonstrated selective agonist activity.

Researchers reported a fast analytical workflow to detect 54 prohibited doping compounds in dried blood spots, serum, and plasma using liquid chromatography and mass spectrometry. The study found that storing samples in dried matrices allows for non-refrigerated transport, reducing costs.

New systematic review in Frontiers in medicine: Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.

Researchers identified LCP2 as a biomarker for chemoresistance in natural killer/T-cell lymphoma. Targeting the LCP2-mediated pathway with Epitalon and Chaetocin helped eliminate therapy-induced senescent cells and improved chemotherapy response in vivo.

Researchers evaluating bovine thymus materials found that supplementation with thymus extracts extended mid-life survival and improved motility in C. elegans. The study suggests these extracts may support healthy aging by protecting against environmental stressors like oxidative damage.

A JBJS Reviews article summarizing injectable peptides in sports medicine concluded that these agents remain experimental, with clinical use limited to approved metabolic agents and rigorous research protocols due to uncertain safety and efficacy.

Researchers analyzed baseline data from clinical trials to quantify sexual activity among women with hypoactive sexual desire disorder. Participants engaged in sexual activity approximately 2.5 times per month despite their condition.

New paper in Journal of clinical medicine: Digitally Guided Hybrid Maxillary Expansion with Supragingival Mandibular Miniplates for Class III Correction in Late Adolescents: A Pilot Clinical Study.

Researchers published a study on the peptide KPV in hepatic HepG2 cells. Treatment with 100 µg/mL KPV significantly reduced lipid accumulation and fatty acid synthase expression induced by oleic acid by regulating the PPARγ pathway.

New review in Frontiers in aging: Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.

New review in Naunyn-Schmiedeberg's archives of pharmacology: Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline.

A systematic review published in Revista medica de Chile suggests that pharmacological activation of ERRα/β/γ receptors may mimic exercise benefits. Animal models show that synthetic pan-ERR agonists like SLU-PP-332 and SLU-PP-915 improve endurance and metabolic health without evident toxicity.

The FDA announced a public advisory committee meeting of the Pharmacy Compounding Advisory Committee to seek input on bulk drug substances nominated for the Section 503A bulk drug substances list.

Researchers published a review of approved and unapproved peptide therapies used in sports medicine. They found that while unapproved peptides often show potential for tissue repair in animal models, human safety data remain scarce and carry a risk of serious harm.

A corrigendum was published for a study evaluating the effects of the neurotrophic peptide mimetic P021 in the 3xTg-AD mouse model of Alzheimer's disease.

Researchers tested the peptide ARA-290 in a mouse model of type 2 diabetes to evaluate cognitive dysfunction. The study found that while ARA-290 improved insulin sensitivity and circulating monocyte proportions, it did not restore executive cognitive flexibility.

A critical review of peptide use in sports concludes that while peptides are marketed as safer alternatives to steroids for bodybuilding, long-term safety data is lacking and the unregulated supply chain poses significant health risks. Evidence for performance enhancement is limited.

Researchers performed a structure-activity relationship analysis of the exercise mimetic compound SLU-PP-332 to understand how its structure controls its efficacy. Several analogues showed improved metabolic stability and solubility compared to the original compound.

A study in the Indian journal of pharmacology investigated Hexarelin's neuroprotective effects on retinal ganglion cells after optic nerve transection in hamsters. Results indicated that Hexarelin increased cell survival in a dose-dependent manner, with 150 μg/kg twice daily being optimal.

Hudson Biotech registered a Phase 2, randomized, double-blind study to evaluate the use of Melanotan II as an adjunct to narrowband UV-B phototherapy in 60 adults with stable nonsegmental vitiligo.

Researchers reported a case of a patient who developed brown pigmentation on the gums and mouth after self-administering Melanotan II for 64 days. While buccal mucosal pigmentation faded after discontinuation, gingival pigmentation persisted for three months.

Molecular medicine issued a retraction for a study on the peptide pHBSP and its ability to attenuate acute kidney injury.

Researchers published a study using diffusion MRI to detect brain microstructure changes in the 3xTg-AD mouse model of Alzheimer's disease following early treatment with the neurotrophic peptide mimetic P021.

Investigators identified 22 metabolites of the exercise mimetic SLU-PP-332 using human liver fractions. These metabolites were categorized for potential use in doping-control screenings to detect illicit use of the substance in sports.

A study in aging mice found that oral supplementation with a bovine thymus nuclear fraction extract reduced neuronal excitability in the brain. The treatment increased levels of GABAergic proteins, suggesting a potential role in mitigating age-related neurotransmission alterations.

Researchers in Frontiers in bioengineering and biotechnology demonstrated that the peptide FOXO4-DRI reduces endothelial cell senescence by inhibiting the binding of FOXO4 to P53. This action activates the p53/BCL-2/Caspase-3 signaling pathway, suppressing aortic aging in mice.

New paper in Rapid communications in mass spectrometry : RCM: In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential.

A review published in the Journal of the American Academy of Orthopaedic Surgeons analyzed the use of therapeutic peptides in orthopaedics. The authors noted that while peptides show promise in preclinical models for tissue regeneration, there is currently a lack of clinical trials.

Researchers characterized SLU-PP-915, an orally bioavailable pan-ERR agonist that enhances aerobic exercise performance. The compound increases exercise capacity and induces Ddit4 gene expression similar to previous non-bioavailable agonists.